| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1553-2712.2011.01150.X |
| P8608 | Fatcat ID | release_3gl3yfv2dzfulnrpvsm22vjera |
| P698 | PubMed publication ID | 21906204 |
| P5875 | ResearchGate publication ID | 51637713 |
| P50 | author | Piotr Ponikowski | Q22114836 |
| Stefan D. Anker | Q30310195 | ||
| Nils G. Morgenthaler | Q114410482 | ||
| Richard M. Nowak | Q114430140 | ||
| Sean-Xavier Neath | Q117275972 | ||
| Christopher Hogan | Q43116966 | ||
| Leong L Ng | Q61120317 | ||
| Gerasimos Filippatos | Q63107352 | ||
| Inder S Anand | Q64438206 | ||
| William Peacock | Q88008306 | ||
| Mark Richards | Q105243769 | ||
| P2093 | author name string | Alan S Maisel | |
| Christian Mueller | |||
| Alan H B Wu | |||
| Robert Christenson | |||
| Lori B Daniels | |||
| Oliver Hartmann | |||
| Martin Möckel | |||
| Salvatore DiSomma | |||
| P2860 | cites work | Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis | Q28305437 |
| Time-dependent ROC curves for censored survival data and a diagnostic marker | Q30600327 | ||
| Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients | Q33206500 | ||
| Adrenomedullin: potential in physiology and pathophysiology | Q33861509 | ||
| C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study | Q34003454 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Cardiac secretion of adrenomedullin in human heart failure | Q37355223 | ||
| Effects of prehospital medications on mortality and length of stay in congestive heart failure | Q43892104 | ||
| Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial | Q44360648 | ||
| Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. | Q45907258 | ||
| Cardiac troponin and outcome in acute heart failure | Q46595726 | ||
| Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay | Q46650090 | ||
| Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis | Q46682108 | ||
| Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin | Q46790418 | ||
| Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study | Q48211868 | ||
| Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure | Q48252671 | ||
| Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure | Q48399609 | ||
| B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. | Q48920074 | ||
| Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. | Q51039466 | ||
| Early Vasoactive Drugs Improve Heart Failure Outcomes | Q57630678 | ||
| P433 | issue | 9 | |
| P921 | main subject | acute decompensated heart failure | Q4677930 |
| heart failure | Q181754 | ||
| P304 | page(s) | 947-958 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Academic Emergency Medicine | Q15755260 |
| P1476 | title | Short-term mortality risk in emergency department acute heart failure | |
| P478 | volume | 18 |
| Q40362800 | Adrenomedullin Is Associated With Surgical Trauma and Impaired Renal Function in Vascular Surgery Patients |
| Q38233991 | BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review |
| Q92300693 | Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM-HF2 trial |
| Q38222370 | Biomarkers for risk prediction in acute decompensated heart failure |
| Q38006640 | Biomarkers in acute heart failure--state of the art. |
| Q26991726 | Cardiac biomarkers: new tools for heart failure management |
| Q26863716 | Clinical adoption of prognostic biomarkers: the case for heart failure |
| Q37734951 | Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial |
| Q38249996 | Copeptin as a biomarker in heart failure |
| Q47689172 | Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure |
| Q38100647 | Heart failure biomarkers |
| Q38232809 | Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review |
| Q38906411 | Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Stud |
| Q38021707 | Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? |
| Q39014581 | Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. |
| Q38667210 | New Targets in the Drug Treatment of Heart Failure |
| Q38131790 | Novel biomarkers for heart failure |
| Q41260247 | Plasma copeptin for short term risk stratification in acute pulmonary embolism |
| Q41520470 | Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis |
| Q48693596 | Prevalence, characteristics and outcome of non-cardiac chest pain and elevated copeptin levels |
| Q37573138 | Prognostic role of copeptin with all-cause mortality after heart failure: a systematic review and meta-analysis |
| Q51507722 | Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study. |
| Q52364966 | Redefining biomarkers in heart failure. |
| Q42948538 | Role of point of care - ST2, Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients |
| Q38568205 | The Current and Potential Clinical Relevance of Heart Failure Biomarkers |
| Q38044782 | The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure |
| Q47969196 | The positive predictive value of ct-proAVP (copeptin) in patients with STEMI. |
| Q34134378 | The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department |
| Q39442697 | Use of copeptin in emergency patients with cardiac chief complaints |
Search more.